AI Article Synopsis
- The study investigated contralateral cranial cruciate ligament rupture (CCLR) in dogs aged 8 and older, weighing over 15 kg, to determine its prevalence and associated risk factors.
- A total of 831 dogs were analyzed, revealing that about 19.1% would experience a CCLR on the opposite side, typically around 12.9 months after the initial diagnosis.
- Significant factors linked to an increased risk included age and specific breeds, particularly Golden and Labrador Retrievers, with the overall prevalence lower than previously thought and the risk decreasing with age.
Article Abstract
Objective: The aim of this study was to determine the prevalence of contralateral cranial cruciate ligament rupture (CCLR) in dogs 8 years of age or older, weighing more than or equal to 15 kg at the time of first-side CCLR and to assess associated risks.
Study Design: It is a cross-sectional retrospective study of 831 client-owned dogs METHODS: Medical records of dogs weighing more than or equal to 15 kgs that were more than or equal to 8 years of age at the time of first CCLR diagnosis were reviewed. Data collected included weight, sex, pre-operative tibial plateau angle, co-morbidities, time between diagnosis of first CCLR and diagnosis of contralateral CCLR. Multivariate logistic regression analysis was used to estimate odds ratio. A median follow-up period of over 112.7 months (25th/75th quartiles 75.4/157.7 months) from first CCLR diagnosis was allotted.
Results: Eight-hundred thirty-one dogs were identified and included. About 19.1% (159/831 dogs, 95% confidence interval: 16.6-22.0%) of dogs that experience a first-side CCLR at 8 years of age or older will rupture the contralateral side, a median of 12.9 months (25th/75th quartiles 6.5/24.3 months) later. Age ( = 0.003) and breed, Golden Retrievers ( = 0.028) and Labrador Retrievers ( = 0.007), were factors significantly associated with contralateral CCLR.
Clinical Relevance: The prevalence of contralateral CCLR in medium-to-large breed dogs more than or equal to 8 years of age old is less than previously reported and the risk decreases as they age. This important information will help guide owners when deciding to pursue surgical stifle stabilization following CCLR in older dogs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0043-1771350 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Solitary Plasmacytoma: Single institution experience and systematic review and meta-analysis of clinical outcomes.
Blood Adv
January 2025
Mayo Clinic, Rochester, Minnesota, United States.
In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic review and meta-analysis of 62 studies, encompassing 3,487 patients from the years 1960 to 2022. Our findings reveal that patients with up to 10% clonal plasma cells in their bone marrow (BM), denoted as plasmacytoma +, had a significantly reduced median disease-free survival (DFS) of 15.7 months vs.
View Article and Find Full Text PDFCo-Designing a Digital Brief Intervention to Reduce the Risk of Prescription Opioid-Related Harm Among People With Chronic Noncancer Pain: Qualitative Analysis of Patient Lived Experiences.
JMIR Form Res
January 2025
Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Background: Opioid medications are important for pain management, but many patients progress to unsafe medication use. With few personalized and accessible behavioral treatment options to reduce potential opioid-related harm, new and innovative patient-centered approaches are urgently needed to fill this gap.
Objective: This study involved the first phase of co-designing a digital brief intervention to reduce the risk of opioid-related harm by investigating the lived experience of chronic noncancer pain (CNCP) in treatment-seeking patients, with a particular focus on opioid therapy experiences.
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
Neurology
February 2025
Department of Neurology and Center of Clinical Neuroscience, First Medical Faculty, General University Hospital and Charles University, Prague, Czech Republic.
Background And Objectives: Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term efficacy and safety profile of the high-efficacy DMT ocrelizumab (OCR) as first-line therapy for early-stage relapsing MS (RMS).
Methods: Post hoc exploratory analyses of efficacy and safety were performed in a subgroup of treatment-naive patients with RMS who received ≥1 dose of OCR in the multicenter OPERA I/II (NCT01247324/NCT01412333) studies.
Characterization of Factors Associated With Death in Deceased Patients With Mitochondrial Disorders: A Multicenter Cross-Sectional Survey.
Neurology
February 2025
Department of Medicine and Geriatrics, Tuen Mun Hospital, Hong Kong, People's Republic of China.
Background And Objectives: Mitochondrial disorders are multiorgan disorders resulting in significant morbidity and mortality. We aimed to characterize death-associated factors in an international cohort of deceased individuals with mitochondrial disorders.
Methods: This cross-sectional multicenter observational study used data provided by 26 mitochondrial disease centers from 8 countries from January 2022 to March 2023.
Outcomes of Home Isolation Care Among COVID-19 Patients During the 2021 Epidemic Crisis in the Bangkok Metropolitan Region, Thailand.
Am J Public Health
January 2025
Teeraboon Lertwanichwattana and Ram Rangsin are with Phramongkutklao College of Medicine, Bangkok, Thailand. Supattra Srivanichakorn, Sairat Noknoy, and Sirinapa Siriporn Na Ratchaseema are with the Royal College of Family Physicians of Thailand, Bangkok. Nittaya Phanuphak is with the Institute of HIV Research and Innovation, Bangkok. Kitti Wongthavarawat is with the National Science and Technology Development Agency, Bangkok. Arunotai Siriussawakul, Varalak Srinonprasert, and Pattara Leelahavarong are with the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok. Parawee Chevaisrakul and Putthapoom Lumjiaktase are with the Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok. Aree Kumpitak is with the Thai Network of People Living With HIV, Bangkok. Nopphan Phromsri is with the Human Settlement Foundation, Bangkok. Yupadee Sirisinsuk is with the Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok. Pongtorn Kietdumrongwong is with the Bangkok Dusit Medical Services, Bangkok. Apinun Aramrattana is with the Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
To determine the overall mortality and risk factors of COVID-19 patients who were admitted to the Home Isolation (HI) program in Bangkok, Thailand, during the epidemic crisis in 2021. We conducted a retrospective cohort study using the data from a government telehealth application from July to December 2021. The vital status was verified from the government database on September 20, 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!